Rheumatology 2000; 39: 975-981
© 2000 British Society for Rheumatology
Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs
University Health Network, Toronto, Ontario, Canada
1 Division of Immunology, Stanford University, Stanford CA, USA,
2 Department of Medicine and The Loeb Health Research Institute, Clinical Epidemiology Unit, University of Ottawa, Ontario,
3 Arthritis & Autoimmunity Research Centre, University Health Network, Toronto, Ontario and Clinical Epidemiology and Healthcare Research Program, University of Toronto, Ontario, Canada
Objective. To summarize the evidence on treatment withdrawal rates reported in observational studies and randomized controlled trials (RCTs) of methotrexate (MTX), parenteral gold (GST), sulphasalazine (SSZ) and hydroxychloroquine (HCQ) among patients with rheumatoid arthritis (RA).
Methods. Two independent Medline searches were used to retrieve relevant studies published between 1966 and 1997. Those which disclosed information on the number of patients withdrawing from the drug were retained. Cumulative probabilities of survival on treatment were then computed using actuarial survival estimates, and differences were tested using log-rank, Wilcoxon and Cox proportional hazards tests.
Results. A total of 159 studies provided withdrawal information, and the numbers of patients who withdrew, in general or because of inefficacy or toxicity, could be abstracted from 110 studies contributing 142 treatment arms (MTX, 48; GST, 56; SSZ, 22; HCQ, 16). Data for HCQ were available only up to 24 months, but combined percentages of patients estimated to have continued MTX, GST or SSZ, respectively, for 60 months were 36, 23 and 22% when all failures were considered, 75, 73 and 53% when withdrawals due to lack of efficacy alone were considered, and 65, 36 and 48% when only withdrawals due to toxicity were taken into account. The Cox proportional hazards test performed on all withdrawals, after adjusting for year of publication and type of study, revealed that patients remained on MTX significantly longer than they did on the other three agents; however, the patients stayed significantly longer on GST than MTX when withdrawals for inefficacy were analysed separately. No significant differences in withdrawal rates were noted between observational studies and RCTs.
Conclusion. Patients with RA stay significantly longer on MTX than on other disease-modifying anti-rheumatic drugs. Higher withdrawal rates among those given GST are mainly due to high toxicity, whereas the majority of withdrawals from SSZ and HCQ result from lack of efficacy. Withdrawal rates in observational studies are similar to those reported in RCTs.
Correspondence to: A. Maetzel, University Health Network, 610 University Avenue, Room 16-741, Toronto, Ontario M5G 2M9, Canada.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. J. Crabtree, A. L. Tatham, A. B. Hale, N. J. Alp, and K. M. Channon Critical Role for Tetrahydrobiopterin Recycling by Dihydrofolate Reductase in Regulation of Endothelial Nitric-oxide Synthase Coupling: RELATIVE IMPORTANCE OF THE DE NOVO BIOPTERIN SYNTHESIS VERSUS SALVAGE PATHWAYS J. Biol. Chem., October 9, 2009; 284(41): 28128 - 28136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Goldbach-Mansky, M. Wilson, R. Fleischmann, N. Olsen, J. Silverfield, P. Kempf, A. Kivitz, Y. Sherrer, F. Pucino, G. Csako, et al. Comparison of Tripterygium wilfordii Hook F Versus Sulfasalazine in the Treatment of Rheumatoid Arthritis: A Randomized Trial Ann Intern Med, August 18, 2009; 151(4): 229 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Donahue, G. Gartlehner, D. E. Jonas, L. J. Lux, P. Thieda, B. L. Jonas, R. A. Hansen, L. C. Morgan, and K. N. Lohr Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis Ann Intern Med, January 15, 2008; 148(2): 124 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M van der Kooij, J. K de Vries-Bouwstra, Y. P M Goekoop-Ruiterman, D. van Zeben, P. J S M Kerstens, A. H Gerards, J. H L M van Groenendael, J. M W Hazes, F. C Breedveld, C. F Allaart, et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score Ann Rheum Dis, October 1, 2007; 66(10): 1356 - 1362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S L Hider, A Silman, D Bunn, S Manning, D Symmons, and M Lunt Comparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritis Ann Rheum Dis, November 1, 2006; 65(11): 1449 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sanmarti, S. Marsal, J. Valverde, E. Casado, R. Lafuente, N. Kashiwagi, J.-R. Rodriguez-Cros, A. Erra, D. Reina, and J. Gratacos Adsorptive granulocyte/monocyte apheresis for the treatment of refractory rheumatoid arthritis: an open pilot multicentre trial Rheumatology, September 1, 2005; 44(9): 1140 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Kinder, A. B. Hassell, J. Brand, A. Brownfield, M. Grove, and M. F. Shadforth The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions Rheumatology, January 1, 2005; 44(1): 61 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Saravanan and C. A. Kelly Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis Rheumatology, February 1, 2004; 43(2): 143 - 147. [Full Text] [PDF]
|
|
|
|
|
|
P. Jobanputra, J. Wilson, K. Douglas, and A. Burls A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis Rheumatology, February 1, 2004; 43(2): 206 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M D Smith, Y Yazici, D Erkan, and M J Harrison Etanercept treatment of rheumatoid arthritis in the "real world" Ann Rheum Dis, January 1, 2003; 62(1): 95 - 96. [Full Text] [PDF]
|
|
|
|
|
|
S E Gabriel, P Tugwell, and M Drummond Progress towards an OMERACT-ILAR guideline for economic evaluations in rheumatology Ann Rheum Dis, April 1, 2002; 61(4): 370 - 373. [Abstract] [Full Text] [PDF]
|
|